荣泰，更专业的按摩椅 上海荣泰健康科技股份有限公司 2022 年半年度报告 2022 年半年度报告 公司代码：603579 公司简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 1 / 179 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人林琪、主管会计工作负责人廖金花及会计机构负责人（会计主管人员）贾晓丽声 明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 2022 年半年度报告 重要提示 七、 是否存在被控股股东及其关联方非经营性占用资金情况 否 八、 是否存在违反规定决策程序对外提供担保的情况？ 否 九、 是否存在半数以上董事无法保证公司所披露半年度报告的真实性、准确性和完整性 否 ...

2022 年第一季度报告 证券代码：603579 证券简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人林琪、主管会计工作负责人廖金花及会计机构负责人贾晓丽（会计主管人员）保证季 度报告中财务报表信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期比上年同期增 减变动幅度(%) | | | | --- | --- | --- | --- | --- | | 营业收入 | 564,797,326.35 | 8.55 | | | | 归属于上市公司股东的净利润 | 58,326,127.42 | | | -15.02 | ...

2021 年年度报告 公司代码：603579 公司简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 2021 年年度报告 1 / 218 2021 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 中汇会计师事务所（特殊普通合伙）为本公司出具了标准无保留意见的审计报告。 四、 公司负责人林琪、主管会计工作负责人廖金花及会计机构负责人（会计主管人员）贾晓丽 声明：保证年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 公司拟以实施利润分配方案时股权登记日的总股本（扣除股份回购专户中的股份数量）为基 数，以未分配利润向全体股东每 10 股派发现金股利人民币 7.00 元（含税），不进行资本公积转 增股本。剩余未分配利润结转以后年度。 六、 前瞻性陈述的风险声明 √适用 □不适用 本年度报告涉及未来计划等前瞻性陈述，不构成公司对投资者的实质承诺，请投 ...

证券代码：603579 证券简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 2021 年第三季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务 报表信息的真实、准确、完整。 2021 年第三季度报告 第三季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 单位：元 币种：人民币 | 项目 | 本报告期 | 本报告期 比上年同 | 年初至报告期末 | 年初至报告 期末比上年 | | --- | --- | --- | --- | --- | | | | 期增减变 | | 同期增减变 | | | | 动幅度(%) | | 动幅度(%) | | 营业收入 | 616,647,798.61 | 17.14 ...

2021 年半年度报告 公司代码：603579 公司简称：荣泰健康 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 2021 年半年度报告 1 / 190 2021 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实、准确、完 整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司全体董事出席董事会会议。 三、 本半年度报告未经审计。 四、 公司负责人 林琪、 主管会计工作负责人廖金花 及会计机构负责人（会计主管人员） 贾晓丽声明：保证半年度报告中财务报告的真实、准确、完整。 五、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 六、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述，不构成公司对投资者的实质承诺，敬请 投资者注意投资风险。 | 第一节 | 释义 4 | | --- | --- | | 第二节 | 公司简介和主要财务指标 5 | | 第三节 | 管理层讨论与分析 7 | | 第四节 | 公司治理 24 | | 第五节 | 环境与社会责任 25 ...

2021 年第一季度报告 | 公司代码：603579 | 公司简称：荣泰健康 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 转股代码：191606 | 转股简称：荣泰转股 | 上海荣泰健康科技股份有限公司 2021 年第一季度报告 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2021 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 3,015,302,869.58 | 2,950,273,548.05 | 2.20 | | | 归属于上市公 | 1,718,216,129.62 | 1,659,416,997.40 | 3.54 | | | 司股东的净资 | | | | | | 产 | | | | | | | 年初至报告期末 | 上年 ...

Financial Performance - The company's operating revenue for 2020 was CNY 2,020,516,424.11, a decrease of 12.68% compared to CNY 2,313,911,804.43 in 2019[21]. - The net profit attributable to shareholders for 2020 was CNY 154,604,149.29, down 37.39% from CNY 246,939,675.87 in 2019[21]. - The basic earnings per share for 2020 was CNY 1.42, a decline of 33.33% from CNY 2.13 in 2019[22]. - The total assets at the end of 2020 reached CNY 2,950,273,548.05, representing a 19.86% increase from CNY 2,461,373,036.61 in 2019[21]. - The weighted average return on equity for 2020 was 12.09%, down 6.81 percentage points from 18.9% in 2019[22]. - The net cash flow from operating activities for 2020 was CNY 275,594,380.01, a decrease of 38.27% compared to CNY 446,466,294.73 in 2019[21]. - The total profit amounted to RMB 198,171,585.37, down 39.54% year-on-year, while the net profit attributable to the parent company was RMB 193,001,094.31, a decline of 34.71%[78]. - The gross profit margin for the manufacturing sector is 30.86%, which represents a decrease of 5.06 percentage points year-over-year[81]. Dividend Policy - The company plans to distribute a cash dividend of RMB 5.00 per 10 shares to all shareholders based on the total share capital on the dividend distribution date, with no capital reserve conversion to share capital[5]. - The cash dividend policy aims to provide stable returns to shareholders while expanding operational scale, with a cash dividend of RMB 5.00 per 10 shares for 2020[132]. - In 2019, the company distributed a cash dividend of RMB 15.00 per 10 shares, reflecting a payout ratio of 69.20%[134]. - The company has a commitment to maintain a clear dividend distribution standard and ensure the rights of minority shareholders are protected[134]. - The company’s profit distribution plan for 2020 was approved, with a total distributable profit of RMB 68.18 million[134]. Audit and Compliance - The company received a standard unqualified audit report from Zhonghui Certified Public Accountants[4]. - The company has not encountered any issues related to accounting errors or non-standard audit opinions during the reporting period[139]. - There were no major lawsuits or arbitration matters reported for the fiscal year 2020, indicating a stable legal standing[142]. - The company has maintained a good integrity status, with no significant overdue debts or court judgments against it[142]. Market Presence and Strategy - The company operates under a multi-channel sales model, including direct sales, e-commerce, and ODM, enhancing its market reach[37]. - The company aims to expand its international market presence through e-commerce channels for its proprietary brands[37]. - The company has established a strong presence in 32 provinces and 2164 cities across China for its shared massage services, boosting brand recognition[40]. - The company plans to open 120 new direct stores and establish a nationwide after-sales service network to enhance customer service and market reach[126]. - The company has implemented a multi-channel marketing strategy, including partnerships with Disney and hosting over 15 Marvel-themed exhibitions to enhance brand recognition among younger consumers[66]. Research and Development - The company emphasizes technological research and development, focusing on innovations in massage performance, product design, and integration of AI and health data monitoring[57]. - R&D expenses were RMB 10,012.13 million, accounting for 4.9% of operating revenue, reflecting a continuous increase in R&D investment[71]. - The company has filed for 38 invention patents and 66 utility model patents during the reporting period, with a total of 383 patents and 38 software copyrights by the end of the period[72]. - The company plans to continue increasing R&D investment to maintain technological leadership in the massage equipment market[129]. Risk Management - The company faces risks from raw material price fluctuations, with over 80% of its cost structure dependent on these materials, which could impact profit growth[124]. - The company will implement measures to mitigate risks from currency fluctuations, primarily by using RMB for contracts and hedging tools[128]. - The company has a significant reliance on BODYFRIEND for sales, which poses a risk if this partnership does not sustain growth[125]. Corporate Governance - The company has established a robust corporate governance structure to protect shareholder rights and ensure fair information disclosure[160]. - The company has a diverse board with members holding various positions in other companies, enhancing its governance and strategic oversight[199]. - The company has not experienced any changes in its controlling shareholder during the reporting period[191]. Community Engagement - The company actively participated in community service, achieving a satisfaction rate of over 98% through various volunteer activities[168]. - In 2020, the company donated a total of 500,000 RMB to the Qingpu Red Cross and 450,000 RMB to the partnered village for pandemic relief efforts[169]. - The company supported 131 distributors by covering their sales staff's salaries for one month, amounting to 3.818 million RMB[171]. Employee Relations - The company organized 12 themed party day activities and 5 training sessions throughout the year to enhance employee education[162]. - The company implemented a training system focused on performance and capability, integrating various training resources to enhance employee skills[163]. - A total of 997 employee health check-ups were arranged in 2020, emphasizing the company's commitment to labor protection[166].

2020 年第三季度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2020 年第三季度报告 1/25 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 8 | 2020 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3/25 单位：元币种：人民币 本报告期末 上年度末 本报告期末比上 年度末增减(%) 总资产 2,225,334,849.07 2,461,373,036.61 -9.59 归属于上市公司股东的净资 产 1,583,364,350.16 1,628,991,717.25 -2.80 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1- ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥878,804,020.34, representing a decrease of 19.90% compared to ¥1,097,111,502.99 in the same period last year[19]. - The net profit attributable to shareholders of the listed company was ¥99,087,263.48, down 27.65% from ¥136,951,416.48 in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥85,470,789.38, a decrease of 10.94% compared to ¥95,973,067.56 in the same period last year[19]. - The net cash flow from operating activities was -¥78,604,171.18, a decline of 133.55% from ¥234,281,882.49 in the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were ¥1,522,860,662.53, down 6.52% from ¥1,628,991,717.25 at the end of the previous year[19]. - Total assets decreased by 9.78%, amounting to ¥2,220,666,018.83 compared to ¥2,461,373,036.61 at the end of the previous year[19]. - Basic earnings per share decreased by 25.51% to CNY 0.73 compared to the same period last year[20]. - Diluted earnings per share also decreased by 25.51% to CNY 0.73 compared to the same period last year[20]. - The weighted average return on equity fell to 6.03%, down 2.81 percentage points from the previous year[20]. - In the first half of 2020, the company's revenue decreased by 19.90% year-on-year, and net profit decreased by 27.65%, showing a gradual reduction in the decline compared to the first quarter where revenue dropped by 36.17% and net profit by 48.75%[52]. Market Presence and Strategy - The company operates under a multi-channel sales model, including direct sales, e-commerce, and ODM for both domestic and international markets[29]. - The company has established a strong presence in the shared massage service market, with operations in 32 provinces and 2,164 cities[34]. - The company focuses on a light-asset model by transferring most self-operated massage chairs to quality operators, enhancing operational efficiency[35]. - The company’s main products include various massage chairs and small massage devices, catering to diverse consumer needs[25][27]. - The company operates under multiple brands, including "Rongtai" and "Momo Da," targeting different consumer segments to effectively capture market share[45]. - The company has established a multi-channel marketing strategy, including e-commerce platforms and physical retail locations, to enhance sales growth[47]. - The company signed a cooperation agreement with Walt Disney (China) Co., Ltd., launching themed exhibitions to enhance brand image and attract younger consumers[54]. - The company achieved a global cumulative sales volume of over 1,700,000 massage chairs by the end of the reporting period, with significant online sales performance during major shopping events[53]. Research and Development - The company emphasizes technological innovation in product development, including AI interaction and health data monitoring, to enhance user experience[44]. - The company increased R&D investment, with 14 ongoing projects and 21 invention patents applied for, enhancing product competitiveness through technological innovation[58]. - Research and development expenses decreased by 19.74% to ¥44,157,071.81 from ¥55,019,384.82 year-on-year[65]. Financial Management - The company implemented a robust accounts receivable and sales credit management mechanism, ensuring good cash flow management and sustainable growth[50]. - The company introduced advanced ERP/MES systems for smart production, optimizing production processes and improving operational efficiency[52]. - The company reported a total profit of ¥104.09 million, down from ¥152.56 million, reflecting a decline of approximately 32%[147]. - The company reported cash inflow from investment activities of CNY 136,869,910.91, a significant improvement from a cash outflow of CNY 161,027,989.05 in the previous year[154]. Risks and Challenges - The company faces risks from raw material price fluctuations, as over 80% of its cost structure is attributed to raw materials, which could impact net profit growth[85]. - The company has a significant reliance on a major client, BODY FRIEND, which poses a risk if sales growth from this client does not continue[86]. - The company is exposed to foreign exchange risks due to its export business primarily settled in USD, which could affect operating performance[88]. - The COVID-19 pandemic has caused significant disruptions to the company's production and sales, leading to potential volatility in performance[91]. Shareholder and Corporate Governance - The company held its first extraordinary general meeting of 2020 on June 29, 2020, where several resolutions regarding the issuance of convertible bonds were approved[95]. - The annual general meeting on April 17, 2020, approved the 2019 annual report and financial statements, including profit distribution proposals[97]. - The company proposed no profit distribution or capital reserve transfer for the half-year period, with no bonus shares or cash dividends declared[98]. - The company confirmed compliance with commitments made by major shareholders and management regarding share transfer restrictions and future plans[99]. - The company reappointed Zhonghui Certified Public Accountants as its auditor for the 2020 financial year during the annual general meeting[102]. Environmental and Compliance - The company does not belong to the key pollutant discharge units and maintains non-severe pollution processes while managing suppliers to comply with environmental production requirements[113]. - The company has not disclosed any significant changes in accounting policies or estimates compared to the previous accounting period[114]. Investment and Capital Structure - The company plans to publicly issue 600 million RMB of convertible bonds to increase production capacity, with a projected design capacity of approximately 720,000 massage chairs upon completion of new projects[62]. - The company repurchased a total of 3,630,263 shares, accounting for 2.59% of the total share capital, with a total payment of approximately RMB 100.61 million[116]. - The total amount allocated for the share repurchase was between RMB 100 million and RMB 200 million[115]. - The company plans to publicly issue convertible bonds, pending approval from the China Securities Regulatory Commission, which carries uncertainty[119].

2020 年第一季度报告 公司代码：603579 公司简称：荣泰健康 上海荣泰健康科技股份有限公司 2020 年第一季度报告 1 / 28 3 / 28 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 11 | 2020 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准 确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法 律责任。 1.2 公司全体董事出席董事会审议季度报告。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度 末增减(%) 总资产 2,316,011,598.50 2,461,373,036.61 -5.91 归属于上市公 司股东的净资 产 1,658,622,459.10 1,628,991,717.25 1.82 年初至报告期末 上年初至上年报告期 末 比上年同期增减(%) 经营活动产生 的现金流量净 额 -227,682,868.54 140,117, ...